Ken Griffin Reviva Pharmaceuticals Holdings, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.64 - $1.48 $11,200 - $25,900	-17,500 Reduced 42.17%	24,000 $34,000
Q2 2024 Aug 14, 2024	SELL	$1.25 - $3.79 $2,500 - $7,580	-2,000 Reduced 4.6%	41,500 $53,000
Q1 2024 May 15, 2024	SELL	$2.76 - $5.52 $544,824 - $1.09 Million	-197,400 Reduced 81.94%	43,500 $164,000
Q4 2023 Feb 14, 2024	SELL	$3.56 - $6.04 $222,856 - $378,104	-62,600 Reduced 20.63%	240,900 $1.24 Million
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.9 $870,757 - $1.31 Million	222,700 Added 275.62%	303,500 $1.48 Million
Q2 2023 Aug 14, 2023	BUY	$4.42 - $8.55 $297,466 - $575,415	67,300 Added 498.52%	80,800 $473,000
Q1 2023 May 15, 2023	SELL	$3.79 - $4.87 $76,558 - $98,374	-20,200 Reduced 59.94%	13,500 $56,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $5.99 $2,016 - $7,188	1,200 Added 3.69%	33,700 $143,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $2.66 $4,550 - $86,450	32,500 New	32,500 $52,000

9.97M

133K

43.9K

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $23.3M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.